Literature DB >> 3621814

Comparison of computed tomography and conventional radiology in the assessment of treatment response of lytic bony metastases in patients with carcinoma of the breast.

E A Bellamy, D Nicholas, M Ward, R C Coombes, T J Powles, J E Husband.   

Abstract

Full skeletal survey, localised radiographs and computed tomography (CT) examinations were compared with clinical assessment in the evaluation of treatment response of bony metastases in 20 patients with carcinoma of the breast. Conventional radiology, skeletal survey and localised views compared poorly with clinical assessment agreeing in only 35% and 50% respectively. CT concurred with the clinical assessment in 65% of patients, particularly with respect to healing (86%). CT predicted the effect of treatment in six additional patients and this was confirmed on follow-up assessment. It is suggested that the use of skeletal surveys in monitoring treatment response is limited and that for critical evaluation of treatment CT should be the method of choice.

Entities:  

Mesh:

Year:  1987        PMID: 3621814     DOI: 10.1016/s0009-9260(87)80207-6

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  10 in total

1.  Osteoblastic response as a healing reaction to chemotherapy mimicking progressive disease in patients with small cell lung cancer.

Authors:  Joerg Stattaus; Steffen Hahn; Thomas Gauler; Wilfried Eberhardt; Stefan P Mueller; Michael Forsting; Susanne C Ladd
Journal:  Eur Radiol       Date:  2008-08-02       Impact factor: 5.315

2.  Reproducibility and clinical correlations of post-treatment changes on CT of prostate cancer bone metastases treated with chemotherapy.

Authors:  S Gourtsoyianni; S Hwang; D M Panicek; J Zheng; C Moskowitz; H Scher; M Morris; H Hricak
Journal:  Br J Radiol       Date:  2012-09       Impact factor: 3.039

3.  Complications in the management of metastatic spinal disease.

Authors:  Eilis Catherine Dunning; Joseph Simon Butler; Seamus Morris
Journal:  World J Orthop       Date:  2012-08-18

Review 4.  Imaging response to systemic therapy for bone metastases.

Authors:  Tobias Bäuerle; Wolfhard Semmler
Journal:  Eur Radiol       Date:  2009-05-26       Impact factor: 5.315

5.  Prostate cancer with lytic bone metastases: 18F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy.

Authors:  Punit Sharma; Sellam Karunanithi; Varun Singh Dhull; Sachin Jain; Chandrasekhar Bal; Rakesh Kumar
Journal:  Indian J Nucl Med       Date:  2013-07

6.  Evaluation of radiographic and metabolic changes in bone metastases in response to systemic therapy with (18)FDG-PET/CT.

Authors:  Bengul Gunalp; Ali Ozan Oner; Semra Ince; Engin Alagoz; Aslı Ayan; Nuri Arslan
Journal:  Radiol Oncol       Date:  2015-03-25       Impact factor: 2.991

7.  Care of cancer patients with liver and bone metastases - the place of pharmaceutical care in a balanced plan, focused on the patient's needs and goals.

Authors:  Katarzyna A Rygiel; Mariola Drozd; Lucyna Bułaś
Journal:  Arch Med Sci       Date:  2016-06-13       Impact factor: 3.318

8.  Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer.

Authors:  T Hamaoka; C M Costelloe; J E Madewell; P Liu; D A Berry; R Islam; R L Theriault; G N Hortobagyi; N T Ueno
Journal:  Br J Cancer       Date:  2010-01-26       Impact factor: 7.640

Review 9.  Multimodal imaging of bone metastases: From preclinical to clinical applications.

Authors:  Stephan Ellmann; Michael Beck; Torsten Kuwert; Michael Uder; Tobias Bäuerle
Journal:  J Orthop Translat       Date:  2015-08-13       Impact factor: 5.191

10.  Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer.

Authors:  Mingxi Lin; Yizi Jin; Ziyi Yang; Xichun Hu; Jian Zhang
Journal:  Ther Adv Med Oncol       Date:  2021-06-15       Impact factor: 8.168

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.